VENUS REMEDIES
|
The Current P/E Ratio of VENUS REMEDIES is 23.55.
| Share Price | ₹1,806.5 | Jul 17,2026 |
| Market Cap | ₹2,420.6 Cr | |
| Earnings-TTM | ₹102.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 23.55x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of VENUS REMEDIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,420.6 Cr] as on Jul 17,2026
(/) Earnings [ ₹102.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 23.55x ]
Thus, for VENUS REMEDIES , the investors are currently willing to pay 23.55 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of VENUS REMEDIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of VENUS REMEDIES over the last five years.
Historical PE (Price/Earnings) ratio chart of VENUS REMEDIES
PE Ratio Performance Analysis for VENUS REMEDIES
- VENUS REMEDIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 9.32x.
- VENUS REMEDIES 's operated at median p/e ratio of 8.82x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, VENUS REMEDIES 's p/e ratio peaked in Mar2024 at 15.31x.
- VENUS REMEDIES 's p/e ratio hit its five-year low in Mar2021 of 5.49x.
How does VENUS REMEDIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| VENUS REMEDIES | 102.80 | 23.55 | 2,420.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 40.11 | 463,815.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 75.03 | 192,678.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 75.46 | 161,323.0 |
| CIPLA LTD | 3,869.79 | 29.61 | 114,585.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 24.39 | 101,067.0 |
| MANKIND PHARMA LTD | 1,926.41 | 53.41 | 102,896.0 |
| LUPIN LTD | 5,355.47 | 20.85 | 111,661.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.68 | 113,990.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 25.21 | 88,265.9 |
| LAURUS LABS LTD | 889.85 | 92.87 | 82,639.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs VENUS REMEDIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 20.85x |
| Max industry PE | 92.87x |
| Median industry PE | 29.61x |
| Average industry PE | 43.92x |
You may also like the below Video Courses